Illumina
(
ILMN
) reported second quarter 2012 EPS of 18 cents, down considerably
from the year-ago level of 22 cents. However, after adjusting for
certain one-time items including impairment charges of 16 cents per
share, EPS for the quarter came in at 40 cents, beating the Zacks
Consensus Estimate of 36 cents as well as the year-ago adjusted EPS
of 38 cents.
The company recorded $21.4 million of impairment charge in the
reported quarter for in-process research and development expenses
associated with an early-stage technology acquired in 2010.
Revenues dipped 2% year over year to $281 million during the
quarter and was affected by robust HiSeq sales in the year-ago
period. Reported revenues were ahead of the Zacks Consensus
Estimate of $277 million. The year-over-year drop in revenues was
primarily due to a 4.1% decline in product revenues, partly offset
by a 23.8% rise in service revenues. The company derives 92.2% of
its total revenue from products while the remaining comes from
services.
Product revenues are primarily attributed to the sale of
Microarrays and DNA Sequencing products. Product revenues consist
of sales proceeds from the Consumables and Instruments segment.
Services and other revenues comprise genotyping and sequencing
services as well as instrument maintenance contracts.
Consumable revenue (consisting 65% of the company's total revenue)
was $184 million, up 16% year over year, resulting from a larger
installed base of both HiSeq and MiSeq. However, Instruments
revenues were down 32% year over year to $72 million in the second
quarter, primarily due to a decrease in sequencing and microarray
instrumentation.
During the quarter, the company introduced BaseSpace Apps, an
application store to access a growing community of academic,
commercial, and open source applications that simplify and
accelerate the analysis of genomic data. BaseSpace pricing for both
data storage and downstream analysis had also been introduced.
Moreover, the company launched MyGenome application for
Apple's
(
AAPL
) iPad for the analysis of real human genome and view reports about
important genetic variation. Further, it introduced a real-time PCR
reagent portfolio (compatible with any real-time PCR platform),
Nextera XT DNA Sample Preparation kits and RapidTrack Whole Genome
Sequencing Service.
Also, during the earnings call, Illumina announced that the Cold
Spring Harbor Laboratory has joined the Illumina Genome Network.
Moreover, the company got a new contract from Queensland Centre for
Medical Genomics, which will replace their fleet of SOLiD/5500
systems with three Illumina HiSeq 2500 systems.
The company's gross margin stood at 68.8% in the reported quarter,
up 150 basis points (bps) year over year. Adjusted gross margin in
the quarter was up 190 bps to 70.9% from 69.0% in the prior-year
period.
Selling, general and administrative (SG&A) expenses were down
1.01% to $68.5 million while adjusted research and development
expenses (excluding $21.4 million of impairment charges) dipped
1.9% to $49.8 million. Adjusted operating margin during the quarter
expanded 110 bps to 26.6%.
Illumina exited the quarter with cash and cash equivalents and
short-term investment of $1.3 billion compared with $1.2 billion at
the end of fiscal 2011. The company generated $96 million in cash
flow from operations in the second quarter versus $71 million in
the prior-year period.
Based on its solid cash balance, Illumina repurchased 800,000
shares for $32 million and has around $200 million remaining for
future repurchases.
Outlook
Illumina reaffirmed its fiscal 2012 revenue guidance of $1.10 -
$1.175 billion (annualized growth of 4% -11%). However, the company
increased its adjusted EPS guidance to $1.50-$1.60 from
$1.40-$1.50. The Zacks Consensus fiscal 2012 revenues estimate of
$1.14 billion remains within the guidance range, while the
consensus EPS estimate of $1.51 remains at the low end of the
company's guidance.
Based in California, Illumina develops, manufactures, and markets
life science tools and integrated systems for the analysis of
genetic variation and function at a broader scale. The company
derives product revenues from the sale of microarrays and DNA
sequencing products.
As a life sciences tools company, Illumina has a track record of
innovation and operational excellence. The company primarily
competes with
Life Technologies Corporation
(
LIFE
) in the sequencing market.
Currently, Illumina retains a short-term Zacks #3 Rank (Hold
rating).
APPLE INC (AAPL): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research